The stock of Bio-Techne Corp (TECH) has seen a 8.15% increase in the past week, with a 1.75% gain in the past month, and a -24.48% decrease in the past quarter. The volatility ratio for the week is 5.45%, and the volatility levels for the past 30 days are at 4.27% for TECH.. The simple moving average for the past 20 days is 3.26% for TECH’s stock, with a -24.95% simple moving average for the past 200 days.
Is It Worth Investing in Bio-Techne Corp (NASDAQ: TECH) Right Now?
Bio-Techne Corp (NASDAQ: TECH) has a higher price-to-earnings ratio of 62.91x compared to its average ratio, The 36-month beta value for TECH is at 1.43. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for TECH is 154.99M, and currently, shorts hold a 4.18% of that float. The average trading volume for TECH on May 14, 2025 was 2.13M shares.
TECH) stock’s latest price update
Bio-Techne Corp (NASDAQ: TECH)’s stock price has gone decline by -4.25 in comparison to its previous close of 53.90, however, the company has experienced a 8.15% increase in its stock price over the last five trading days. prnewswire.com reported 2025-05-12 that MINNEAPOLIS, May 12, 2025 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13 th – 17th at the New Orleans Ernest N. Morial Convention Center.
Analysts’ Opinion of TECH
Evercore ISI, on the other hand, stated in their research note that they expect to see TECH reach a price target of $75. The rating they have provided for TECH stocks is “Outperform” according to the report published on March 18th, 2025.
Robert W. Baird gave a rating of “Neutral” to TECH, setting the target price at $68 in the report published on February 19th of the current year.
TECH Trading at -6.11% from the 50-Day Moving Average
After a stumble in the market that brought TECH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.69% of loss for the given period.
Volatility was left at 4.27%, however, over the last 30 days, the volatility rate increased by 5.45%, as shares sank -1.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.66% lower at present.
During the last 5 trading sessions, TECH rose by +8.15%, which changed the moving average for the period of 200-days by -34.40% in comparison to the 20-day moving average, which settled at $49.98. In addition, Bio-Techne Corp saw -28.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECH starting from Herr Amy E., who sale 1,860 shares at the price of $65.96 back on Feb 14 ’25. After this action, Herr Amy E. now owns 1,976 shares of Bio-Techne Corp, valued at $122,691 using the latest closing price.
JOSHUA MOLHO, the Domestic Partner of Director of Bio-Techne Corp, proposed sale 1,860 shares at $65.96 during a trade that took place back on Feb 14 ’25, which means that JOSHUA MOLHO is holding shares at $122,691 based on the most recent closing price.
Stock Fundamentals for TECH
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.66 for the gross margin
The net margin for Bio-Techne Corp stands at 0.11. The total capital return value is set at 0.08. Equity return is now at value 6.53, with 4.91 for asset returns.
Based on Bio-Techne Corp (TECH), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at 0.63. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 30.02.
Currently, EBITDA for the company is 310.37 million with net debt to EBITDA at 0.99. When we switch over and look at the enterprise to sales, we see a ratio of 6.93. The receivables turnover for the company is 5.1for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
In conclusion, Bio-Techne Corp (TECH) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
